超声引导下微波与射频消融治疗原发性甲状旁腺功能亢进:一项前瞻性多中心研究
这项前瞻性多中心研究在五个中心纳入132例原发性甲状旁腺功能亢进患者共141个甲状旁腺结节,行超声引导下微波或射频消融,技术成功率99.29%,治愈率80.30%,消融前PTH水平是与治愈率相关的独立因素,微波组与射频组治愈率无差异,主要并发症为声音嘶哑(5.30%)。
要点
- 超声引导下微波或射频消融治疗原发性甲状旁腺功能亢进技术成功率99.29%、治愈率80.30%。
- 消融前PTH水平是与治愈率相关的独立因素(OR 0.22;95%CI 0.07-0.69;p=0.0090)。
- 微波组与射频组治愈率无差异(80.22% vs 80.49%,p=0.971),主要并发症为声音嘶哑(5.30%)。
核心结论
- 超声引导下微波和射频消融治疗原发性甲状旁腺功能亢进是有效且安全的方法,消融前PTH水平是影响消融后治愈率的关键因素。
研究设计与样本
- 前瞻性多中心研究,2017年8月至2020年10月在五个中心纳入132例原发性甲状旁腺功能亢进患者共141个甲状旁腺结节,行超声引导下微波或射频消融,消融前后行实验室检查并随访至少6个月。
诊断标准与关键数值
- 技术成功率99.29%(140/141);随访6-36个月(中位12个月),治愈率80.30%(106/132);消融前PTH水平与治愈率相关(OR 0.22;95%CI 0.07-0.69;p=0.0090);微波组与射频组治愈率无差异(80.22% vs 80.49%,p=0.971)。
临床应用与阅片要点
- 消融前PTH水平是影响原发性甲状旁腺功能亢进微波或射频消融后治愈率的独立因素,微波与射频两种方式治愈率无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To prospectively investigate the efficacy and safety of ultrasound (US)-guided microwave ablation (MWA) and radiofrequency ablation (RFA) for primary hyperparathyroidism (PHPT).
METHODS: We performed a prospective multicenter study of MWA and RFA for PHPT between August 2017 and October 2020 at five centers. Laboratory testing was performed pre- and post-ablation and followed for at least 6 months. The primary outcome was the cure rate. Secondary outcomes were complications and dynamic changes in serum levels of PTH, calcium, phosphorus, and ALP after ablation.
RESULTS: A total of 132 participants (mean age, 57.33 ± 13.90 years), with 141 parathyroid nodules (median maximal diameter, 1.55 cm) undergoing either MWA or RFA, were enrolled in the study. The technique success rate was 99.29% (140/141). The follow-up period was 6-36 months (median, 12 months). The cure rate was 80.30% (106/132). Pre-ablation PTH level was the independent factor associated with cure rate (Odds ratio (OR), 0.22; 95% CI, 0.07-0.69; p = 0.0090). There was no difference in cure rate between the MWA group and the RFA group (80.22% vs. 80.49%, p = 0.971). The only main complication was hoarseness (5.30%).
CONCLUSIONS: US-guided MWA and RFA for PHPT is an effective and safe procedure in the treatment of PHPT. Pre-ablation PTH level is the key factor affecting the cure rate after MWA and RFA.
KEY POINTS: • To our knowledge, this is the first prospective multicenter clinical trial with ultrasound-guided MWA and RFA for primary hyperparathyroidism. • There was no difference in cure rate between the MWA and RFA groups for primary hyperparathyroidism. The overall cure rate was 80.30%. • Pre-ablation PTH level was the independent factor associated with cure rate (odds ratio (OR), 0.22; 95% CI, 0.07-0.69; p = 0.0090).
引用
- Liu, Liu, Peng, et al. Ultrasound-guided microwave and radiofrequency ablation for primary hyperparathyroidism: a prospective, multicenter study. Eur Radiol. 2022. PMID: 35593958. doi:10.1007/s00330-022-08851-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。